A recently-published study funded by the UK National Institute for Health and Care Research finds that use of OTC nasal sprays reduces overall respiratory illness duration by about a fifth. Applied at a population level, self-care could therefore save billions in healthcare and human capital costs, as industry has pointed out elsewhere, as well as redirecting people away from antibiotic treatments that are still widely misprescribed, contributing to the fight against antimicrobial resistance.
Use of commonly available OTC nasal sprays reduces the severity of, and shortens the length of time people suffer from, respiratory illnesses, a recently-published study has found.
By treating the symptoms of such illnesses, which are mostly viral in origin, the nasal sprays studied – Procter and...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
